Patient | Biopsied blastocysts, n | Grade of blastocysts | Molecular karyotype | Predictive results | Karyotype of amniotic fluid | |
Family member* | Unbalanced embryo† | |||||
Patient 1 | Embryo 1 | 5BC | UPD (1–22,X) | NA | NA | |
Embryo 7 | 5BC | (1–22)*2, (XN)*1 | Carrier | NA | No pregnancy | |
Embryo 8 | 5BB | (1–22)*2, (XN)*1 | Carrier | NA | Carrier | |
Embryo 9 | 6BB | 5*3; 10*3 | Normal | NA | ||
Patient 2 | Embryo 1 | 5BC | (1–22)*2, (XN)*1 | NA | Normal | Normal |
Embryo 6 | 5AB | 1p36.33p21.3*1; 1q31.3q44*3 | NA | Unbalanced | ||
Embryo 7 | 5BC | 1p36.33p21.3*3; 1q31.3q44*1 | NA | Unbalanced | ||
Embryo 10 | 5BC | 1p36.33p21.3*1; 1q31.3q44*3 | NA | Unbalanced | ||
Patient 3 | Embryo 1 | 5BC | (1–22)*2, (XN)*1 | Carrier | NA | Carrier |
Embryo 2 | 5BC | (1–22)*2, (XN)*1 | Carrier | NA | Not transplanted | |
Patient 4‡ | Embryo 1-1 | 5BB | 19*1 | Normal | NA | |
Embryo 1-2 | 6BB | 7p22.3*3; 7q32.3q36.3*1; 15*3 | Carrier | Unbalanced | ||
Embryo 2-1 | 5CB | (1–22)*2, (XN)*1 | Normal | Normal | No pregnancy | |
Embryo 2-3 | 5CB | (1–22)*2, (XN)*1 | Carrier | Carrier | Carrier | |
Embryo 2-5 | 5CB | (1–22)*2, (XN)*1 | Carrier | Carrier | Not transplanted | |
Embryo 2-6 | 5BC | 7p22.3*3; 7q32.3q36.3*1 | Carrier | Unbalanced | ||
Embryo 2-8 | 5BB | 22*1 | Normal | Normal | ||
Embryo 2-10 | 5BC | 14*1 | Carrier | Carrier |
*In patients 1, 3 and 4, family member was used as a reference to phase haplotype analysis to predict the karyotype of diploid embryo.
†In patients 2 and 4, the unbalanced embryo was used as a reference to phase haplotype analysis to predict the karyotype of diploid embryo. In patient 2, embryos 6, 7 and 10 were used as a reference; in patient 4, embryo 1-2 and embryo 2-6 were used as a reference.
‡In patient 4, the embryos were from two COH cycles, embryo 1-1 and embryo 1-2 were from the first COH cycle, the other embryos were from the second COH cycle.
COH, controlled ovarianhyper-stimulation; NA, not applicable.